Form 4: BridgeBio Pharma Director Acquires Stock Options
SEC Form 4 Filing
Douglas A. Dachille, a director of BridgeBio Pharma, acquired stock options for 26,014 shares on June 21, 2024.
Summary
- On June 21, 2024, Douglas A. Dachille, a director at BridgeBio Pharma, acquired stock options for 26,014 shares of common stock.
- The exercise price of these options is $27.36.
- The options vest in three equal annual installments starting June 21, 2024, and will be fully vested by June 21, 2027, contingent upon continued service on the board.
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a routine regulatory filing detailing stock option acquisition.
Future Outlook
The vesting of the stock options is contingent upon the reporting person's continued service on the board of directors.
Industry Context
This is a standard Form 4 filing, indicating a change in beneficial ownership by a company insider. Such filings are common and provide transparency into insider transactions.
Stakeholder Impact
- The acquisition of stock options by a director can be seen as a positive sign, aligning the director's interests with those of the shareholders.
Key Dates
| Date | Description |
|---|---|
| 06/21/2024 | Date of stock option acquisition and first vesting date. |
| 06/20/2034 | Expiration date of the stock options. |
| 06/21/2027 | Date when all stock options will be fully vested. |
| 06/25/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.